Navigation Links
Ottawa researchers discover new combination therapy to kill cancer

OTTAWA, ON January 27, 2014 Cancer is the leading cause of death in Canada and is responsible for about 30% of all deaths, according to the Canadian Cancer Society. Despite the urgent need for new and effective drugs, it remains extremely difficult to develop anti-cancer therapies in a timely way. Researchers in Ottawa looked at how to leverage current experimental therapies, in different combinations, to speed the fight against cancer. Scientific evidence suggests a specific combination approach is effective, as published today in Nature Biotechnology.

"We are very excited about this novel combination approach and are looking to move this experimental therapy into clinical trials as soon as possible," said Dr. Robert Korneluk, distinguished professor at the University of Ottawa and senior scientist at the CHEO Research Institute. "I firmly believe that it's not a matter of 'if' this will help cancer patients but 'when' this therapy becomes a standard of care."

Worldwide evidence has already shown that two immunotherapies are promising. The first, SMAC Mimetics, is an IAP-based therapy that targets cancer-causing genes. IAPs were discovered at CHEO 19 years ago. The second, live virus therapies, or oncolytics, are a separate field of study booming in Ottawa. Both of these immunotherapies are in clinical trials now and although the results are encouraging, neither, as a stand-alone therapy, have yet to show substantial effects. That is until a team of scientists led by Dr. Korneluk discovered that combining SMAC Mimetics together with a live virus (or even other non-viral immune stimulators), results in a synergistic, or amplified, tumour-killing effect, which overcomes the limitation of either agent on its own.

"Our combination approach is quite different than standard chemotherapy treatments that can have significant negative side-effects," continued Dr. Korneluk. "Instead, we looked at combining two novel experimental cancer drugs that we already know work on the immune system. The results of our combination exceeded expectations and furthermore, no harm was done to the surrounding healthy tissue when we eradicated tumours."

In some cases, tumours required 10,000-times less virus to kill a cancer cell when a SMAC mimetic was added. The combined use of these two drugs could possibly save years of clinical development time, allowing for faster patient access to these drugs. The research team postulates that this combination approach is likely better suited for specific cancers and specific uses. For example, tumours which cannot be surgically removed but which can be injected with a cancer-killing virus are good candidates.


Contact: Adrienne Vienneau
613-737-7600 x4144
Children's Hospital of Eastern Ontario Research Institute

Related biology news :

1. Ottawa researchers to lead world-first clinical trial of stem cell therapy for septic shock
2. Cleveland Clinic researchers discover process that turns good cholesterol bad
3. Researchers discover potential drug targets for early onset glaucoma
4. Researchers identify innate channel that protects against pain
5. Combustion continues to draw researchers to space station
6. Curtin researchers to hide our splashes from sharks
7. Researchers discover how heart arrhythmia occurs
8. Researchers collaborate to reduce effects of the aging eye
9. 1 step at a time, researchers learning how humans walk
10. Researchers discover that coevolution between humans and bacteria reduces gastric cancer risk
11. Researchers identify key components linking circadian rhythms and cell division cycles
Post Your Comments:
(Date:5/6/2017)... 2017 RAM Group , Singaporean ... breakthrough in biometric authentication based on a ... to perform biometric authentication. These new sensors are based ... by Ram Group and its partners. This sensor will ... chains and security. Ram Group is a next ...
(Date:4/17/2017)... , April 17, 2017 NXT-ID, Inc. ... company, announces the filing of its 2016 Annual Report on Form ... Exchange Commission. ... Form 10-K is available in the Investor Relations section of the ... on the SEC,s website at . 2016 ...
(Date:4/11/2017)... Research and Markets has announced the addition of the ... ... grow at a CAGR of 30.37% during the period 2017-2021. ... prepared based on an in-depth market analysis with inputs from industry ... over the coming years. The report also includes a discussion of ...
Breaking Biology News(10 mins):
(Date:10/11/2017)... ... 2017 , ... Personal eye wash is a basic first aid supply for any work environment, ... eye do you rinse first if a dangerous substance enters both eyes? It’s one less ... with its unique dual eye piece. , “Whether its dirt and debris, or an acid ...
(Date:10/11/2017)... ... October 11, 2017 , ... Proscia Inc ., a ... Webinar titled, “Pathology is going digital. Is your lab ready?” with Dr. Nicolas ... practices and how Proscia improves lab economics and realizes an increase in diagnostic ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/11/2017)... Austin, TX (PRWEB) , ... October 11, 2017 ... ... in August compared the implantation and pregnancy rates in frozen and fresh ... the contribution of progesterone and maternal age to IVF success. , After comparing ...
Breaking Biology Technology: